Sandoz' Biosimilar Etanercept On Its Way To EU Market
This article was originally published in Scrip
Executive Summary
The EMA has accepted for review a biosimilar etanercept product from Novartis's Sandoz division. The biosimilar version of Pfizer's TNF-inhibitor Enbrel has been filed for use in all the indications detailed in Enbrel's label, including rheumatoid arthritis and psoriasis.
You may also be interested in...
Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing
Sandoz has used data extrapolation to all the indications for Roche's MabThera in its marketing submission for biosimilar rituximab, just accepted for review by the European Medicines Agency.
Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing
Sandoz has used data extrapolation to all the indications for Roche's MabThera in its marketing submission for biosimilar rituximab, just accepted for review by the European Medicines Agency.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.